Baird raised the firm’s price target on Twist Bioscience (TWST) to $50 from $33 and keeps an Outperform rating on the shares. The firm uppdated its model following Q4 results where the company raised its 2026 revenue guidance on broad based momentum.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST: